Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 5:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1297–1320 of 3,253 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Acute Pain, Pediatric ALL, Procedural Pain, Burns
Interventions: VR-PAT; Other
Lead sponsor: Nationwide Children's Hospital; Other
Eligibility: 6 Years to 17 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Procedural Pain, Procedural Anxiety
Interventions: Virtual Reality (VR) Audiovisual Distraction; Behavioral
Lead sponsor: University of California, Davis; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Sacramento, California

Conditions: Gestational Diabetes, Postpartum
Interventions: Dexcom Stelo real-time Continuous Glucose Monitor; Device
Lead sponsor: Oregon Health and Science University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 3
States / cities: Santa Barbara, California • Portland, Oregon • Philadelphia, Pennsylvania

Conditions: Post-Cardiac Arrest Syndrome
Interventions: Xenon; Combination Product
Lead sponsor: Invero Pharma, Inc.; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 1,436 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 8
States / cities: Hartford, Connecticut • Gainesville, Florida • Gulfport, Mississippi + 5 more

Conditions: Mycoplasma Genitalium Infection, Urethritis
Interventions: Omadacycline Oral Tablet; Drug
Lead sponsor: Montefiore Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027
U.S. locations: 1
States / cities: The Bronx, New York

Conditions: Neoplasms (Cancer / Tumors), Colorectal Neoplasms, Lung Neoplasms, Endometrial Neoplasms, Breast Neoplasms, Pancreatic Neoplasms, Head and Neck Neoplasms, Kidney Neoplasms, Glioma, Ovarian Neoplasms, Stomach Neoplasms
Interventions: Not listed
Lead sponsor: Harvard Medical School (HMS and HSDM); Other
Eligibility: Not listed
Enrollment: 30,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Ovarian Neoplasms, Endometrial Cancer, Endometrial Neoplasm
Interventions: BMX-001, Paclitaxel (Taxol); Drug
Lead sponsor: BioMimetix JV, LLC; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 27 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Blood Pressure, Relaxation, Virtual Reality
Interventions: Virtual Reality Relaxation, Video Meditation, Live Guided; Behavioral
Lead sponsor: University of Miami; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Epithelial Ovarian Cancer, Gastro-esophageal Junction Cancer, Soft Tissue Sarcoma (STS), Myxoid Liposarcoma, Synovial Sarcoma
Interventions: Lymphodepletion, TCR-T cells (MDG1015); Drug · Biological
Lead sponsor: Medigene AG; Industry
Eligibility: 18 Years and older
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2042
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Obesity, Weight Loss, Body Weight, Nonalcoholic Steatohepatitis, Nonalcoholic Fatty Liver Disease, NAFLD
Interventions: Embospheres Microspheres; Device
Lead sponsor: Keith Pereira, MD:; Other
Eligibility: 22 Years to 65 Years
Enrollment: 8 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1
Interventions: Asciminib, Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Corticosteroid, Cytarabine, Dexamethasone, Echocardiography Test, Methotrexate, Vincristine; Drug · Procedure · Biological
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Duarte, California

Conditions: Concussion (Diagnosis)
Interventions: Nature-based Guided Awareness Group, Standard Guided Awareness Group; Behavioral
Lead sponsor: Penn State University; Other
Eligibility: 14 Years to 35 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: University Park, Pennsylvania

Conditions: Heart Failure, Heart Failure, Systolic
Interventions: Pharmacist/Cardiologist Virtual Team Digital Consultation; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years and older
Enrollment: 585 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Neurofibromatosis 1 (NF1)
Interventions: mirdametinib with radiation, mirdametinib; Combination Product · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 12 Years to 89 Years
Enrollment: 55 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Joint Discomfort, Wellbeing, Quality of Life
Interventions: Undenatured collagen, Whole salmon oil; Dietary Supplement
Lead sponsor: Hofseth Biocare ASA; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 150 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Advanced Endometrial Carcinoma, Metastatic Endometrial Carcinoma, Recurrent Endometrial Carcinoma, Stage III Endometrial Cancer, Stage IV Endometrial Cancer
Interventions: Biospecimen Collection, Computed Tomography, Elacestrant, Everolimus, Magnetic Resonance Imaging, Positron Emission Tomography, Questionnaire Administration; Procedure · Drug · Other
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Ductus Arteriosus, Patent
Interventions: Transcatheter PDA Closure; Device
Lead sponsor: Le Bonheur Children's Hospital; Other
Eligibility: 3 Days to 1 Year
Enrollment: 5,000 participants
Timeline: 2020 – 2031
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Tobacco Use Disorder, Smoking Cessation
Interventions: Nicotine Polacrilex Gum (2 mg), Cognitive Behavioral Group Therapy (CBGT); Drug · Behavioral
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years to 80 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Cytomegalovirus (CMV), Anterior Uveitis, Infectious Uveitis, CMV Infection
Interventions: Valganciclovir, Ganciclovir (GCV), Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2032
U.S. locations: 2
States / cities: Los Angeles, California • San Francisco, California

Conditions: Biomarkers, Acute Kidney Injury, Sepsis
Interventions: Not listed
Lead sponsor: Nutromics; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 5
States / cities: Oakland, California • San Francisco, California • Stanford, California + 2 more

Conditions: Oral Cavity Squamous Cell Carcinoma
Interventions: Chemotherapy, Lattice Radiotherapy (LRT); Drug · Radiation
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Lung Cancer
Interventions: Witness Project Lung, General Educational Program; Behavioral
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 50 Years to 80 Years
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Nutley, New Jersey

Conditions: Subjective Cognitive Complaints, Ehlers-Danlos Syndrome, Cognitive Dysfunction
Interventions: COG+OT Telerehabilitation; Behavioral
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 18 Years to 99 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 2
States / cities: Charleston, South Carolina

Conditions: Chemotherapy Exposure, Handling Guidelines, Oncology Nurse, Adherence
Interventions: The Workplace program to Improve the Safe Handling of hazardous drugs (WISH); Behavioral
Lead sponsor: University of Cincinnati; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Cincinnati, Ohio

Search by objective public record fields.

VR-PAT and fNIRS to Identify CNS Biomarkers of Pain

Virtual Reality (VR) Audiovisual Distraction to Reduce Pain and Anxiety for Prone Pain Procedures

Stelo Real-time Continuous Glucose Monitor Use Postpartum for Lifelong Optimal Wellness

Xenon for Neuroprotection During Post-Cardiac Arrest Syndrome in Comatose Survivors of an Out of Hospital Cardiac Arrest

Omadacycline for Treatment Refractory Mycoplasma Genitalium Urethritis

A Preregistered Multi-Cohort Evaluation of the FATHOM AI System for Molecular Testing Prioritization to Support Clinical Trial Enrollment

BMX-001 + Paclitaxel in Adult Patients With Advanced, Recurrent, Metastatic Ovarian or Endometrial Cancer

Consciousness Studies and Cardiovascular Health

EPITOME-1015-I: a Study to Investigate the Safety and Tolerability of MDG1015 in Patients with Epithelial Ovarian Cancer, Gastroesophageal Adenocarcinoma, Round Cell Liposarcoma And/or Synovial Sarcoma

Bariatric Embolization of Arteries for the Treatment of Nonalcoholic Steatohepatitis

Asciminib-Based Induction Therapy for the Treatment of Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Nature as Medicine for the Healing Brain: Utilization of a Nature-based Exposure Intervention for Decreasing Concussion Recovery Timeline and Symptom Load

Pharmacist-Assisted Titration of Rx to Implement Optimal Medical Therapy for Heart Failure

Efficacy of Mirdametinib Alone or Combination With Radiotherapy for Germline and Sporadic NF1-Altered High-Grade Glioma

Assessing the Potential for Improved Joint Health and Wellbeing by Providing a Whole Salmon Oil With Undenatured Type II Collagen Compared to Type II Collagen Alone

Elacestrant With Everolimus for the Treatment of Recurrent Advanced or Metastatic ER-Positive Endometrial Cancer

The U.S. PDA Registry

Quit-Smoking Study for Native Hawaiians

Systemic and Topical Antiviral Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes - Trials I and II

Vancomycin Exposure and Biomarker Tracking Using Real-time Monitoring of Interstitial Fluid

Lattice-Based Radiotherapy and Chemo-Immunotherapy for Oral Cavity Squamous Cell Carcinoma

Witness Project Lung

COG+OT Telerehabilitation for Adults With Subjective Cognitive Complaints

Promoting Adherence to Chemotherapy Handling Guidelines Among Oncology Nurses